Analysts expect that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will report $0.18 earnings per share for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Amphastar Pharmaceuticals’ earnings. The highest EPS estimate is $0.27 and the lowest is $0.09. Amphastar Pharmaceuticals posted earnings per share of $0.10 during the same quarter last year, which indicates a positive year over year growth rate of 80%. The company is scheduled to issue its next earnings results on Monday, March 11th.

According to Zacks, analysts expect that Amphastar Pharmaceuticals will report full-year earnings of $0.31 per share for the current fiscal year, with EPS estimates ranging from $0.18 to $0.44. For the next financial year, analysts anticipate that the business will report earnings of $0.86 per share, with EPS estimates ranging from $0.53 to $1.25. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Thursday, November 8th. The company reported $0.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.01. The firm had revenue of $75.54 million during the quarter, compared to analysts’ expectations of $76.84 million. Amphastar Pharmaceuticals had a negative net margin of 2.33% and a positive return on equity of 2.80%. The firm’s revenue for the quarter was up 30.5% compared to the same quarter last year. During the same period last year, the firm posted $0.07 earnings per share.

AMPH has been the subject of a number of research reports. BidaskClub upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 9th. Needham & Company LLC reduced their target price on shares of Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday, August 10th. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 10th. ValuEngine upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 17th. Finally, Wells Fargo & Co restated a “buy” rating on shares of Amphastar Pharmaceuticals in a report on Friday, November 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Amphastar Pharmaceuticals has a consensus rating of “Buy” and an average target price of $23.60.

In related news, General Counsel Jason B. Shandell sold 16,095 shares of the firm’s stock in a transaction that occurred on Friday, November 9th. The shares were sold at an average price of $20.99, for a total value of $337,834.05. Following the completion of the transaction, the general counsel now owns 204,805 shares of the company’s stock, valued at approximately $4,298,856.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Yakob Liawatidewi sold 17,808 shares of the firm’s stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $20.97, for a total transaction of $373,433.76. Following the completion of the transaction, the senior vice president now directly owns 46,763 shares of the company’s stock, valued at approximately $980,620.11. The disclosure for this sale can be found here. Insiders have sold 84,560 shares of company stock valued at $1,768,672 over the last 90 days. 31.50% of the stock is currently owned by insiders.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in Amphastar Pharmaceuticals by 4.7% in the 3rd quarter. BlackRock Inc. now owns 5,987,805 shares of the company’s stock worth $115,205,000 after purchasing an additional 267,622 shares during the period. Dimensional Fund Advisors LP boosted its stake in Amphastar Pharmaceuticals by 7.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,909,883 shares of the company’s stock worth $36,746,000 after purchasing an additional 140,350 shares during the period. Federated Investors Inc. PA boosted its stake in Amphastar Pharmaceuticals by 21.6% in the 2nd quarter. Federated Investors Inc. PA now owns 1,276,552 shares of the company’s stock worth $19,480,000 after purchasing an additional 227,142 shares during the period. Bank of New York Mellon Corp boosted its stake in Amphastar Pharmaceuticals by 2.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 418,903 shares of the company’s stock worth $8,060,000 after purchasing an additional 10,837 shares during the period. Finally, Cortina Asset Management LLC boosted its stake in Amphastar Pharmaceuticals by 49.9% in the 2nd quarter. Cortina Asset Management LLC now owns 392,296 shares of the company’s stock worth $5,986,000 after purchasing an additional 130,604 shares during the period. 42.89% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:AMPH traded up $0.79 during trading hours on Thursday, reaching $20.92. 200,700 shares of the company’s stock were exchanged, compared to its average volume of 192,079. The stock has a market capitalization of $971.39 million, a price-to-earnings ratio of 55.05, a PEG ratio of 9.82 and a beta of 1.38. Amphastar Pharmaceuticals has a 12 month low of $14.40 and a 12 month high of $21.65. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.34 and a current ratio of 2.02.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

See Also: Stock Symbol

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.